Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Entera Bio (ENTX) EBITDA Margin (2019 - 2025)

Entera Bio has reported EBITDA Margin over the past 6 years, most recently at 6102.38% for Q1 2025.

  • For the quarter ending Q1 2025, EBITDA Margin changed N/A year-over-year to 6102.38%, compared with a TTM value of 27419.05% through Dec 2025, down 2212347.0%, and an annual FY2025 reading of 27450.0%, down 2215442.0% over the prior year.
  • EBITDA Margin came in at 6102.38% for Q1 2025, down from 2850.0% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6043.31% in Q1 2021 to a low of 35812.5% in Q3 2022.
  • Median EBITDA Margin over the past 4 years was 4718.98% (2024), compared with a mean of 6720.17%.
  • The sharpest move saw EBITDA Margin soared 657491bps in 2021, then tumbled -3757036bps in 2022.
  • Over 4 years, EBITDA Margin stood at 2477.58% in 2021, then crashed by -785bps to 21914.29% in 2022, then skyrocketed by 87bps to 2850.0% in 2024, then tumbled by -114bps to 6102.38% in 2025.
  • Per Business Quant, the three most recent readings for ENTX's EBITDA Margin are 6102.38% (Q1 2025), 2850.0% (Q4 2024), and 7192.86% (Q3 2024).